Annovis Bio Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.16 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.27Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $54.2M Enterprise Value $35.5M Shares Outstanding 42.7M diluted Next Earnings Date31 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing buntanetap, a novel oral therapy targeting multiple neurotoxic proteins for neurodegenerative diseases like Alzheimer's (AD) and Parkinson's (PD). While the company has achieved significant clinical milestones—including reaching 85% enrollment in its pivotal Phase 3 AD trial and initiating a PD open-label extension (OLE) study—it remains a pre-revenue entity with a high cash burn rate. The recent capital raises, including a $15 million public offering in May 2026, have helped extend its operational runway, but the company continues to face substantial going-concern risks and dilution potential. Given the binary nature of upcoming Phase 3 clinical readouts and the immediate need for further financing to sustain operations into 2027, a Hold recommendation is warranted until clear efficacy data and a stabilized capital structure are established. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$8.00 Mean target$11.00 High · most bullish analyst$17.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The Phase 3 AD trial fails to meet its primary cognitive and functional endpoints, or the FDA raises safety concerns that halt development. The company is unable to raise additional capital on favorable terms, leading to severe dilution or operational restructuring. Cash reserves are depleted by late 2026, forcing a suspension of clinical programs. Base CaseCentral scenario The pivotal Phase 3 AD trial achieves full enrollment in Summer 2026, leading to a successful 6-month symptomatic readout in early 2027. Annovis successfully files its first NDA for symptomatic treatment of early AD in 2027, followed by a disease-modifying NDA in early 2028. The company secures additional dilutive or non-dilutive financing to bridge its cash runway through these regulatory milestones, gradually re-rating the stock toward historical analyst targets. Bull CaseUpside scenario Buntanetap successfully meets primary endpoints in the Phase 3 AD trial, demonstrating both robust symptomatic efficacy in Q1 2027 and disease-modifying properties in Q1 2028. This leads to rapid FDA approvals, successful commercial launch, and potential expansion into Parkinson's disease dementia, driving exponential valuation growth. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |